Sign Up
OverviewAPI
Vertex Pharmaceuticals secures CHMP positive opinion for CASGEVY™, a CRISPR/Cas9 gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, potentially marking the first genetic therapy for eligible patients in the EU.

Ask a question